Nuvalent
planned first in human phase study | Nuvalent
Company
Deck Type
IPO
Sector
Industry
Deck date
July 2021
Slide
22 of 40
Related slides by other companies
MindMed
Investor Presentation
January 2025
regulatory elements supporting filing requirements | MindMed
Dare Bioscience
Investor Presentation
February 2023
cream phase ongoing phase clinical study aims to evaluate cream placebo over weeks of dosing following both a non drug and placebo run in period compares cream placebo used in patients home setting primary patient reported outcome pro instruments to measure improvement in localized genital sensations of arousal and reduction in related distress several exploratory efficacy will be measured and could become additional measurements of efficacy in a future phase program topline data of phase respond study targeted for | Dare Bioscience
MindMed
Investor Presentation
June 2023
phase study results key phase study results support progression of results from phase progression of clinical trial demonstrate tolerability and support linear maintained across the tested doses and clinical effects align with potent regimen suitable regimen in withdrawal aligns with preclinical evidence offers potential to be a more frequencies engagement | MindMed
Dare Bioscience
Investor Presentation
July 2023
cream phase respond study overview | Dare Bioscience
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights